Evidence map›Paper›PMID 28973009›Full record

ArticlePloS one2017

TLR9 stimulation of B-cells induces transcription of p53 and prevents spontaneous and irradiation-induced cell death independent of DNA damage responses. Implications for Common variable immunodeficiency.

Kristine Lillebø Holm, Randi Gussgard Syljuåsen, Grete Hasvold, Lene Alsøe, Hilde Nilsen, Kristina Ivanauskiene, Philippe Collas, Sergey Shaposhnikov, Andrew Collins, Randi Larsen Indrevær and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Heat KilledJournal of oncology · 2021
    Article
  3. Heat-killedThe Journal of international medical research · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kristine Lillebø HolmDepartment of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-1688-7262
Randi Gussgard SyljuåsenDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
Grete HasvoldDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
Lene AlsøeDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Hilde NilsenDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Kristina IvanauskieneDepartment of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Philippe CollasDepartment of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Sergey ShaposhnikovComet Biotech AS, Norgenotech AS, Oslo, Norway.
Andrew CollinsComet Biotech AS, Norgenotech AS, Oslo, Norway.
Randi Larsen IndreværDepartment of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Pål AukrustSection of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Børre FevangSection of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Heidi Kiil BlomhoffDepartment of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-8537-5439
University of Oslo · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, we address the important issue of whether B-cells protected from irradiation-induced cell death, may survive with elevated levels of DNA damage. If so, such cells would be at higher risk of gaining mutations and undergoing malignant transformation. We show that stimulation of B-cells with the TLR9 ligands CpG-oligodeoxynucleotides (CpG-ODN) prevents spontaneous and irradiation-induced death of normal peripheral blood B-cells, and of B-cells from patients diagnosed with Common variable immunodeficiency (CVID). The TLR9-mediated survival is enhanced by the vitamin A metabolite retinoic acid (RA). Importantly, neither stimulation of B-cells via TLR9 alone or with RA increases irradiation-induced DNA strand breaks and DNA damage responses such as activation of ATM and DNA-PKcs. We prove that elevated levels of γH2AX imposed by irradiation of stimulated B-cells is not due to induction of DNA double strand breaks, but merely reflects increased levels of total H2AX upon stimulation. Interestingly however, we unexpectedly find that TLR9 stimulation of B-cells induces low amounts of inactive p53, explained by transcriptional induction of TP53. Taken together, we show that enhanced survival of irradiated B-cells is not accompanied by elevated levels of DNA damage. Our results imply that TLR9-mediated activation of B-cells not only promotes cell survival, but may via p53 provide cells with a barrier against harmful consequences of enhanced activation and proliferation. As CVID-derived B-cells are more radiosensitive and prone to undergo apoptosis than normal B-cells, our data support treatment of CVID patients with CpG-ODN and RA.

Indexed as

DNA DamageInfrared RaysB-LymphocytesCase-Control StudiesCommon Variable ImmunodeficiencyHumansToll-Like Receptor 9Transcription, GeneticTumor Suppressor Protein p53TLR9 protein, humanToll-Like Receptor 9Tumor Suppressor Protein p53

Identifiers

PMID28973009
PMCPMC5626471
OpenAlexW2762022668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.